Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 15, 2018
IN 2017 VIFOR PHARMA RECORDED A STRONG FINANCIAL PERFORMANCE DRIVEN BY ITS THREE MEDIUM-TERM STRATEGIC GROWTH-DRIVERS AND THE SUCCESSFUL DIVESTITURE OF ITS NON-CORE WHOLESALE/RETAIL PHARMACY...
-
Mar 8, 2018
Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update effective immediately in the US THE UNITED STATES (US) FOOD AND DRUG ADMINISTRATION (FDA) HAS...
-
Feb 8, 2018
VIFOR PHARMA ANNOUNCED TODAY THAT VIT-2763, THE FIRST-EVER ORAL FERROPORTIN INHIBITOR FOR PREVENTING IRON OVERLOAD WILL ENTER CLINICAL DEVELOPMENT WITH A PHASE-I STUDY AT THE BEGINNING OF MARCH...
-
Jan 4, 2018
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney...
-
Jan 4, 2018
Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM...
-
Nov 23, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Sep 27, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 8, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 21, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 18, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases